TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04760262
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Study: NCT03514277
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
Study: NCT03514277
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mL bupivacaine 0.5% w/v solution
Study: NCT00033618
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02489240
Drug: vitamin D3 tablets
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU vitamin D3 tablets were taken daily for 6 days
Study: NCT00414167
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg per day for 8 weeks
Study: NCT02713477
Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02713477
Drug: Insulin glargine HOE901
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00759772
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mcg sc daily for 6 months
Study: NCT02866032
Drug: Ciclopirox 80 mg/g
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04480775
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transversus abdominis plane block with bupivacain and triamicinolone
Study: NCT04480775
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transversus abdominis plane block with bupivacaine and methylprednisolone
Study: NCT04480775
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transversus abdominis plane block with bupivacaine alone
Study: NCT03948867
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
Study: NCT04039373
Drug: BMS-986256
Normalized name: BMS-986256
DrugBank: Afimetoran (DB16580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: specified dose on specified days
Study: NCT04039373
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: specified dose on specified days
Study: NCT01809860
Drug: isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01809860
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT00239408
Drug: tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00600743
Drug: GSKI181771X (CCK-1R agonist)
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug one trial vs placebo
Study: NCT01305408
Drug: Armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Armodafinil tablets, taken orally, once daily in the morning
Study: NCT01162486
Drug: Rifampin & midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT01162486
Drug: rifapentine & midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT01162486
Drug: rifapentine & midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT01162486
Drug: rifapentine & midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT01162486
Drug: rifapentine and midazolam
Normalized name: Rifapentine
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT00099489
Drug: Interferon Beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04136535
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed，500mg/m²，ivgtt ，d1，q3w
Study: NCT04136535
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin，AUC 5.0，ivgtt，d1，q3w，
Study: NCT04136535
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib ，12 mg，po，qd，d1-14，q3w；
Study: NCT01162486
Drug: rifapentine and midazolam
Normalized name: Rifapentine
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT03952091
Drug: TJ202, Lenalidomide and Dexamethasone
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
Study: NCT02676986
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-androgen
Study: NCT02676986
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (Licenced)
Study: NCT02952573
Drug: JNJ-42756493
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing
Study: NCT02952573
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
Study: NCT01716208
Drug: Ofatumumab + Fresh Frozen Plasma
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04299633
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 2 x 150 mg oral tablets
Study: NCT03952091
Drug: Lenalidomide and Dexamethasone
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
Study: NCT04299633
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 800 mg oral tablets
Study: NCT01839097
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~* Cohort 1: belinostat 1000 mg/m2 IV on Day 1~* Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~* Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~* Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~* Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5
Study: NCT01839097
Drug: CHOP
Normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat.
Study: NCT02440425
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
Study: NCT00724425
Drug: IPI-493
Normalized name: IPI-493
DrugBank: IPI-493 (DB13023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Multiple Schedules
Study: NCT02440425
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: 80 mg/m\^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
Study: NCT00981825
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole mouth brushing for 7 days
Study: NCT00981825
Drug: Triclosan/Fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth twice daily for 7 days
Study: NCT01998789
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
Study: NCT01998789
Drug: Standard Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels.
Study: NCT01818531
Drug: Adductor canal block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01818531
Drug: Lumbar plexus block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01531777
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study: NCT01531777
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study: NCT00795275
Drug: Sitagliptin Phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
Study: NCT02700360
Drug: EC-18
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
Study: NCT00842244
Drug: axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT00842244
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
Study: NCT01696955
Drug: Tivantinib
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04137328
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
Study: NCT04137328
Drug: insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
Study: NCT03349502
Drug: MG4101
Normalized name: ALLOGENEIC NATURAL KILLER CELL LINE MG4101
DrugBank: MG-4101 (DB18906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
Study: NCT04213118
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg QD PO d1-14, 21 days per cycle.
Study: NCT00543023
Drug: teriparatide 20 micrograms/day subcutaneous
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00543023
Drug: salmon calcitonin 100 IU/day subcutaneous
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218270
Drug: Tobacco free snuff
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco free snuff
Study: NCT02847286
Drug: Dapivirine Ring-004
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Dapivirine Ring-004 for 28 days
Study: NCT02847286
Drug: Dapivirine Ring-004 for 28 days along with clotrimazole
Normalized name: Actonel with Calcium 28 Day Pack
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
Study: NCT02847286
Drug: Clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment C: Clotrimazole, 5 g per day for 7 days
Study: NCT00825149
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine will be administered as per schedule specified in the respective arm.
Study: NCT00825149
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as per schedule specified in the respective arm.
Study: NCT00413205
Drug: RAR Gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg po daily
Study: NCT00623805
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was supplied as a solution in single-use vials.
Study: NCT00623805
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin was supplied as a lyophilized powder in vials.
Study: NCT02856100
Drug: 18F DCFPyL- Radiopharmaceutical
Normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00825149
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab will be administered as per schedule specified in the respective arm.
Study: NCT00825149
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone will be administered as per schedule specified in the respective arm.
Study: NCT00825149
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine will be administered as per schedule specified in the respective arm.
Study: NCT00311987
Drug: 3,5-Diiodothyropropionic acid (DITPA) therapy
DrugBank: 3,5-diiodothyropropionic acid (DB12629)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04658732
Drug: Administration of Alprazolam , Gabapentin , Dexmedetomidine
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
Study: NCT00407862
Drug: Telmisartan 80 mg
Normalized name: telmisartan 80 MG
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00407862
Drug: Losartan 50 mg
Normalized name: losartan 50 mg oral tablet
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00925678
Drug: DSP-3025
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01304082
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml subcutaneous injection of 0.9% lidocaine, given once
Study: NCT01304082
Drug: alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
Study: NCT02733042
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an IV infusion (250 mL) over approximately 1 hour in duration
Study: NCT02733042
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02733042
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by intravenous infusion
Study: NCT02733042
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02733042
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as a 30-minute intravenous infusion
Study: NCT03522987
Drug: Escitalopram 10mg
Normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
Study: NCT01620736
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg po bid
Study: NCT02397460
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
Study: NCT01818700
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 8weeks treatment with Norspan®(Buprenorphine)
Study: NCT01400464
Drug: Prednisone therapy and pharmacokinetic
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
Study: NCT02228473
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate will be administered.
Study: NCT02228473
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine will be administered.
Study: NCT01531140
Drug: polyethylene glycol +Bisacodyl
Normalized name: Polyethylene Glycol
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
Study: NCT01531140
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol p.o.: 60 ml/kg/days
Study: NCT01531140
Drug: Sennosides
Normalized name: Sennosides
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sennosides 1tbl/8kg for 2 days
Study: NCT00999973
Drug: Mitomycin C 0.02%
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no